Congress Asset Management Co. Buys 8,681 Shares of Repligen Corporation $RGEN

Key Points

• Congress Asset Management increased its Repligen stake by 0.9%, adding 8,681 shares to own 1,020,907 shares valued at approximately $196.2 million, or 1.81% of the company.
• Institutional investors and hedge funds own 97.64% of Repligen, with several major funds recently establishing new positions.
• Repligen shares fell 7.7% to $174.86, while the company reported quarterly EPS and revenue above analyst expectations. Analysts maintain a “Moderate Buy” consensus with an average price target of $168.57.

Congress Asset Management Co. boosted its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 0.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,020,907 shares of the biotechnology company's stock after purchasing an additional 8,681 shares during the quarter. Repligen comprises about 1.2% of Congress Asset Management Co.'s holdings, making the stock its 11th largest position. Congress Asset Management Co. owned 1.81% of Repligen worth $196,249,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. United Capital Financial Advisors LLC acquired a new position in shares of Repligen in the second quarter valued at approximately $380,756,000. Maverick Capital Ltd. purchased a new stake in Repligen in the 1st quarter worth approximately $178,946,000. Wasatch Advisors LP acquired a new position in Repligen in the 1st quarter valued at $146,513,000. William Blair Investment Management LLC purchased a new position in shares of Repligen during the 2nd quarter worth $107,593,000. Finally, Bamco Inc. NY acquired a new stake in shares of Repligen during the second quarter worth $102,121,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Down 7.7%

RGEN traded down $14.64 during trading on Tuesday, hitting $174.86. 1,704,621 shares of the company's stock were exchanged, compared to its average volume of 1,036,977. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $198.87. The stock has a 50 day moving average price of $171.55 and a 200 day moving average price of $142.00. The firm has a market cap of $9.87 billion, a P/E ratio of 239.53, a price-to-earnings-growth ratio of 3.32 and a beta of 1.08. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same quarter last year, the firm posted $0.26 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts expect that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on RGEN shares. JPMorgan Chase & Co. upped their target price on Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Wells Fargo & Company upped their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an "overweight" rating in a research note on Thursday, July 30th. UBS Group reissued a "buy" rating on shares of Repligen in a research report on Tuesday, September 29th. Benchmark upgraded shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $168.57.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company's portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.